Device Trial Radar · NCT04303897
Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma
Last checked: Nov 19, 2026Latest source record: Apr 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Dec 19, 2019
Primary completion
Mar 3, 2022
Study completion Mar 3, 2022
Sponsor
- Lead sponsor
- AllerganNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 11, 2020
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Real-world evidence study to assess the safety and effectiveness of XEN® Glaucoma Treatment System in Chinese patients with refractory glaucoma. Participants will be (prospective) or have already been (retrospective) implanted with XEN via specific urgent medical need.
Conditions
- Refractory Glaucoma
Interventions
XEN Glaucoma StentDevice
Data are collected from patients who are implanted with XEN via the specific urgent medical needs for named patient use regulatory pathway in Hainan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients achieving at least a 20% reduction from intraocular pressure (IOP) while on the same number or fewer number of IOP lowering medications than at baselineTime frame: Baseline to Month 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Boao Super Hospital /ID# 233669
Qionghai, Hainan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.